Antipseudomonal Antibiotics for Adult Patients
Antipseudomonal antibiotics are specific agents with reliable activity against Pseudomonas aeruginosa and include β-lactams (piperacillin-tazobactam, cefepime, ceftazidime, carbapenems, aztreonam), fluoroquinolones (ciprofloxacin, levofloxacin), aminoglycosides (amikacin, gentamicin, tobramycin), and polymyxins (colistin, polymyxin B). 1
β-Lactam Agents (Primary Antipseudomonal Coverage)
The β-lactam antibiotics form the backbone of antipseudomonal therapy and are categorized into several classes:
Antipseudomonal Penicillins
- Piperacillin-tazobactam 4.5 g IV q6h - This is the most commonly recommended antipseudomonal penicillin 1
Antipseudomonal Cephalosporins
- Cefepime 2 g IV q8h - Broad-spectrum fourth-generation cephalosporin 1
- Ceftazidime 2 g IV q8h - Third-generation cephalosporin with enhanced antipseudomonal activity 1
Carbapenems
- Meropenem 1 g IV q8h - Preferred carbapenem for antipseudomonal coverage 1
- Imipenem 500 mg IV q6h - Alternative carbapenem (dose may need reduction in patients <70 kg to prevent seizures) 1
Monobactams
- Aztreonam 2 g IV q8h - Particularly useful in patients with severe β-lactam allergies, as it can be combined with other β-lactams due to different cell wall targets 1
Non-β-Lactam Agents
Fluoroquinolones
- Ciprofloxacin 400 mg IV q8h - Most potent antipseudomonal fluoroquinolone 1
- Levofloxacin 750 mg IV daily - Alternative fluoroquinolone with antipseudomonal activity 1
Aminoglycosides
Critical caveat: Aminoglycosides should never be used as the sole antipseudomonal agent, as meta-analyses show lower clinical response rates with aminoglycoside monotherapy 1. All aminoglycosides require drug level monitoring and dose adjustment 1.
Polymyxins (Reserve Agents)
- Colistin - 5 mg/kg IV loading dose, followed by maintenance dosing based on creatinine clearance 1
- Polymyxin B - 2.5-3.0 mg/kg/day divided in 2 daily doses 1
Important limitation: Polymyxins should be reserved for settings with high prevalence of multidrug resistance and require local expertise in administration 1.
Newer Agents
Recent evidence highlights novel β-lactam/β-lactamase inhibitor combinations:
- Ceftolozane-tazobactam - Most frequently prescribed in real-world practice (64.7% of cases) 2
- Ceftazidime-avibactam - Second most common (20.2% of cases) 2
- Cefiderocol - New siderophore cephalosporin showing promising results against resistant P. aeruginosa 3
Clinical Decision-Making Algorithm
When to Use Single vs. Double Antipseudomonal Coverage
Use DOUBLE antipseudomonal coverage (two agents from different classes) when:
- Prior IV antibiotic use within 90 days 1
- Septic shock at time of infection 1
- High risk of mortality (ventilatory support, septic shock) 1
- Structural lung disease (bronchiectasis, cystic fibrosis) 1
- Local unit prevalence of resistant Pseudomonas >10-20% 1
When combining agents, avoid using two β-lactams together (exception: aztreonam can be combined with another β-lactam due to different bacterial targets) 1.
Use SINGLE antipseudomonal agent when:
- No risk factors for multidrug resistance
- Low mortality risk
- No recent antibiotic exposure 1
Pharmacokinetic Optimization
Extended or continuous infusions of β-lactams are appropriate and may improve outcomes, particularly for:
Extended 3-hour infusions of ceftazidime 2 g q8h and meropenem 2 g q8h achieve optimal pharmacodynamic exposure for late-onset pneumonia 4. However, real-world data from 2026 showed no independent mortality benefit from prolonged/continuous infusion compared to standard infusion, with outcomes more strongly associated with baseline severity markers 2.
Common Pitfalls to Avoid
- Never use aminoglycosides as monotherapy for antipseudomonal infections 1
- Do not combine two β-lactams (except aztreonam) - select agents from different classes 1
- Ceftriaxone and ertapenem lack antipseudomonal activity - do not use for Pseudomonas coverage 4
- Always check local antibiograms - resistance patterns vary significantly by institution 1
- Adjust dosing for renal/hepatic dysfunction - particularly critical for aminoglycosides and polymyxins 1
Resistance Considerations
Uniform susceptibility (100%) has been reported for piperacillin, meropenem, amikacin, and polymyxin B in some surveillance studies 5, though this varies by geographic location and institution. The emergence of multidrug-resistant strains necessitates continuous antimicrobial surveillance programs 3, 5. Resistance mechanisms include drug-inactivating enzymes (metallo-β-lactamases), outer membrane impermeability, and active efflux pumps 5.